Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1959 Oct 17;2(5154):740–742. doi: 10.1136/bmj.2.5154.740

An Appraisal of Phenylbutazone Suppositories

C F Hawkins, H T Fawns
PMCID: PMC1990226  PMID: 14400253

Full text

PDF
740

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BENSTEAD J. G. Deaths of two patients treated by phenylbutazone. Br Med J. 1953 Mar 28;1(4812):711–712. doi: 10.1136/bmj.1.4812.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BEUTLER E., BERGENSTAL D. M. Perforated duodenal ulcer with neutropenia and death in a patient receiving phenylbutazone therapy. Gastroenterology. 1953 Sep;25(1):72–74. [PubMed] [Google Scholar]
  3. BRUCK E., FEARNLEY M. E., MEANOCK I., PATLEY H. Phenylbutazone therapy; relation between the toxic and therapeutic effects and the blood level. Lancet. 1954 Jan 30;266(6805):225–228. doi: 10.1016/s0140-6736(54)90874-0. [DOI] [PubMed] [Google Scholar]
  4. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  5. CUDKOWICZ L., JACOBS J. H. Phenylbutazone (butazolidine) in the treatment of chronic arthritis. Lancet. 1953 Jan 31;1(6753):223–224. doi: 10.1016/s0140-6736(53)90891-5. [DOI] [PubMed] [Google Scholar]
  6. DILLING N. V. Fatal agranulocytosis and gastric ulceration due to phenylbutazone. Lancet. 1953 Jun 20;1(6773):1230–1231. doi: 10.1016/s0140-6736(53)92260-0. [DOI] [PubMed] [Google Scholar]
  7. KELLY M. Phenylbutazone (butazolidin); good or evil? Antirheumatic or analgesic? Med J Aust. 1954 Sep 25;2(13):504–507. [PubMed] [Google Scholar]
  8. LEONARD J. C. Toxic effects of phenylbutazone with special reference to disorders of the blood. Br Med J. 1953 Jun 13;1(4823):1311–1313. doi: 10.1136/bmj.1.4823.1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MACCARTHY J. M., JACKSON R. T. Hepatic necrosis and other visceral lesions associated with phenylbutazone therapy. Br Med J. 1955 Jul 23;2(4933):240–242. doi: 10.1136/bmj.2.4933.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. MCMAHON M. F. Clinical effects of Butazolidin. Rheumatism. 1957 Jan;13(1):17–19. [PubMed] [Google Scholar]
  11. MUIR A., COSSAR I. A. Aspirin and ulcer. Br Med J. 1955 Jul 2;2(4930):7–12. doi: 10.1136/bmj.2.4930.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. RAFFENSPERGER E. C. Multiple gastric ulcers occurring during phenylbutazone therapy. J Am Med Assoc. 1953 May 2;152(1):30–31. doi: 10.1001/jama.1953.63690010006007e. [DOI] [PubMed] [Google Scholar]
  13. SANDWEISS D. J. Effects of adrenocorticotropic hormone (ACTH) and of cortisone on peptic ulcer. I. Clinical review. Gastroenterology. 1954 Nov;27(5):604–616. [PubMed] [Google Scholar]
  14. STEPHENS C. A. L., Jr, YEOMAN E. E., HOLBROOK W. P., HILL D. F., GOODIN W. L. Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis. J Am Med Assoc. 1952 Nov 15;150(11):1084–1086. doi: 10.1001/jama.1952.03680110024007. [DOI] [PubMed] [Google Scholar]
  15. VON RECHENBERG H. K. Rheumatherapie mit Butazolidin; Klinische Erfahrungen mit 3, 5-Dioxo-1, 2-diphenyl-4-n-butyl-pyrazolidin-Natrium, einem neuen Pyrazolderivat. Schweiz Med Wochenschr. 1953 Feb 14;83(7):159–164. [PubMed] [Google Scholar]
  16. WILKINSON E. L., BROWN H. The effect of butazolidin (phenylbutazone) on water and electrolyte excretion. Am J Med Sci. 1953 Feb;225(2):153–158. doi: 10.1097/00000441-195302000-00007. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES